Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Tobias Holderried

Professor of Cellular Immunotherapy

Medical University of Graz

Research Interests

Explore related searches

Articles (20)

Collaborators (10)

Christof Scheid

University of Cologne

Udo Holtick

University Hospital

Olaf Penack

David Michonneau

Assistance Publique - Hôpitaux de Paris

Wolfgang Bethge

Deputy Medical Director

University Hospital Tübingen

Daniele Avenoso

Professore Associato

University of Brescia

Amir Jazaeri

The University of Texas MD Anderson Cancer Center

UNITED STATES

Christian Sebastian Michel

Attending physician, Head of Myeloma Service

University Medical Center of the Johannes Gutenberg University Mainz

Jason J. Luke

UNITED STATES

Nausheen Ahmed

Assistant Professor

University of Kansas Medical Center

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tobias Holderried

Research Interests

Explore related searches

Articles (20)

Collaborators (10)

Christof Scheid

Udo Holtick

Olaf Penack

David Michonneau

Wolfgang Bethge

Daniele Avenoso

Amir Jazaeri

Christian Sebastian Michel

Jason J. Luke

Nausheen Ahmed

Make your next move.

Tobias Holderried

Research Interests

Explore related searches

Articles (20)

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis

Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis

High-dose MTX-based polychemotherapy for primary CNS lymphoma in younger patients: Long-term efficacy of the modified Bonn protocol

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study

Retrospective analysis of 300 microbial cell-free DNA sequencing results in routine blood stream infection diagnostics

Systematic Review and Meta-Analysis of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Sequential Dosing of Next-Generation IMA203CD8 TCR-T-Cell Therapy Targeting PRAME in Combination with BRAF-/MEK-Inhibition in a Melanoma Patient with Progressive Disease - a Case Report

Collaborators (10)

Christof Scheid

Udo Holtick

Olaf Penack

David Michonneau

Wolfgang Bethge

Daniele Avenoso

Amir Jazaeri

Christian Sebastian Michel

Jason J. Luke

Nausheen Ahmed

Make your next move.